35 NE Industrial Rd
61 articles with Isoplexis
IsoPlexis Reports First Quarter 2022 Financial ResultsFirst quarter 2022 revenue increased 52% over prior year period
IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022.
IsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable GrowthReiterates full year guidance and extends cash runway to H2 2024
IsoPlexis Corporation, the Superhuman Cell Company, announced its preliminary unaudited revenue for the first quarter of 2022 and the transition to an integrated commercial and operational structure, which is intended to ensure a sustainable growth path.
IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022
IsoPlexis Corporation (NASDAQ: ISO ), the Superhuman Cell Company, today announced that data generated using its Duomic™ platform demonstrates the ability to connect T Cell Receptor (TCR) diversity to the most functionally potent single cells.
Many human diseases have been linked to malformed or malfunctioning proteins. Sickle cell disease is one example.
IsoPlexis Corporation today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022.
IsoPlexis Corporation, the Superhuman Cell Company, announced the company will be participating in the following investor conferences.
IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell PublicationSingle-cell functional proteomics identifies biological factors and immune cell types that drive Long COVID in convalescent COVID-19 patients
IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell Company, today announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium.
2/4/2022Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
IsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Manager, APAC Region
IsoPlexis, the Superhuman Cell Company, announced the opening of its first office in the Asia-Pacific region headed by Jason Ou as President/General Manager, APAC Region.
IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library
IsoPlexis, the Superhuman Cell Company, announced its preliminary unaudited revenue for the full year 2021.
IsoPlexis today announced that new data generated on its IsoLight® platform will be presented at the 63rd annual American Society of Hematology (ASH) conference, taking place December 11-13 at the Georgia World Congress Center in Atlanta, Georgia.
IsoPlexis today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller.
IsoPlexis Corporation today announced the company will be participating virtually in the upcoming Evercore ISI 4th Annual HealthCONx Conference.
IsoPlexis Corporation, the leader in functional single-cell proteomics, announced the publication of two high-impact clinical research studies in Nature Medicine.
IsoPlexis, the leader in functional single-cell proteomics, announced the appointment of two new leadership positions at the company.
IsoPlexis Corporation today announced that data generated on its IsoLight® and IsoSpark® Platforms will be presented at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 11th
10/13/2021Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week.
IsoPlexis Corporation, a leader in functional single-cell proteomics, announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.
Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
IsoPlexis Corporation, a leader in functional single-cell proteomics, announced the pricing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.